The results showed that SKB264 had a stronger targeting effect and excellent antitumor activity with favorable ADC stability and safety profiles, suggesting the potential clinical utility of SKB264 for treating cancers with TROP2 overexpression. Here, TACSTD2 is linked to cancer.